Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00064103
Other study ID # NCI-2012-02541
Secondary ID MDA-ID-00193P50C
Status Completed
Phase Phase 1/Phase 2
First received July 8, 2003
Last updated January 22, 2013
Start date June 2003

Study information

Verified date January 2013
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase I/II trial is studying the side effects and best dose of gene therapy and to see how well it works in preventing cancer in patients with premalignant carcinoma of the oral cavity or pharynx. Inserting the p53 gene into a person's tumor cells may improve the body's ability to kill the tumor cells


Description:

OBJECTIVES:

I. Determine the acute toxic effects of Ad5CMV-p53 gene administered as an oral rinse and as an intramucosal injection in patients with diffuse premalignant carcinoma of the oral cavity or oral pharynx.

II. Determine the maximum tolerated dose of this drug in these patients. III. Determine the topical transduction efficiency of adenoviral-mediated wild type p53 gene transfer in patients treated with this drug.

IV. Determine the efficacy of this drug in reversing the histology of oral premalignancies in these patients.

V. Determine the distribution of transgenic protein within the area of the premalignant lesion in patients treated with this drug.

OUTLINE: This is an open-label, dose-escalation study of Ad5CMV-p53 gene administered as an oral rinse.

Phase I: Patients receive Ad5CMV-p53 gene by intramucosal injection into the area of the lesion followed at least 2 hours later by Ad5CMV-p53 gene as an oral rinse on day 1. Patients then receive Ad5CMV-p53 gene as an oral rinse twice daily on days 2-5. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of Ad5CMV-p53 gene as an oral rinse until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Phase II: Patients receive treatment with intramucosal Ad5CMV-p53 gene as in phase I and Ad5CMV-p53 gene as an oral rinse at the MTD. Patients are followed every 3 months for 1 year, every 6 months for 1 year, and then annually for 3 years. Patients then receive long-term follow-up annually for an additional 10 years.


Recruitment information / eligibility

Status Completed
Enrollment 51
Est. completion date
Est. primary completion date August 2007
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically confirmed mild to moderate dysplasia OR severe dysplasia/carcinoma in situ of the oral cavity or oral pharynx

- Clinically evident diffuse premalignant disease, defined by 1 of the following mucosal abnormalities:

- Extension between adjacent organ structures (e.g., lateral tongue, ventral tongue, and the floor of the mouth)

- Extensive surface area, including the entire ventral tongue or floor of the mouth or buccal mucosa, in a velvety "indiscreet" pattern

- Meets 1 of the following criteria:

- Previously treated with conventional treatment (e.g., radiotherapy or surgery) for a prior head and neck malignancy

- Failed biochemoprevention approaches for premalignant disease

- Failed other therapeutic approaches for premalignant disease

- No active squamous cell carcinoma of the head and neck

- Performance status - Karnofsky 70-100%

- Absolute granulocyte count at least 2,000/mm^3

- Platelet count at least 100,000/mm^3

- Bilirubin no greater than 1.0 mg/dL

- Creatinine no greater than 1.5 mg/dL

- No hypertension (baseline blood pressure 140/90 mm Hg or higher)

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective barrier contraception during and for 1 year after study participation

- HIV-1 negative

- No known contact with former tissue or organ transplantation recipients or individuals with severe immunodeficiency disease (acquired or congenital) during and for 28 days after study treatment

- No prior malignancy within the past 2 years except nonmelanoma skin cancer or aerodigestive cancer

- No active systemic viral, bacterial, or fungal infections requiring treatment

- No serious concurrent illness that would preclude study compliance and follow-up

- No psychological, familial, sociological, geographical, or other condition that would preclude study compliance and follow-up

- See Disease Characteristics

- More than 21 days since prior chemotherapy (42 days for mitomycin and nitrosoureas)

- No concurrent systemic chemotherapy

- No concurrent prednisone or the equivalent, including corticosteroids of more than 10 mg/day

- See Disease Characteristics

- More than 3 months since prior radiotherapy involving the lesion selected for this study

- No concurrent radiotherapy

- See Disease Characteristics

- More than 8 weeks since prior investigational agents

- No prior experimental therapy (i.e., oral, systemic, topical, or direct injection) for the lesion selected for treatment in this study

- No other concurrent immunosuppressive therapy

- No other concurrent investigational agents

- No concurrent aspirin dose greater than 175 mg/day

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention


Intervention

Biological:
Ad5CMV-p53 gene
Given intramucosally or as oral rinse
Other:
laboratory biomarker analysis
Correlative studies

Locations

Country Name City State
United States M D Anderson Cancer Center Houston Texas

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Frequency of adverse events Up to 15 years Yes
Primary Severity of adverse events graded using the CTCAE version 3.0 Up to 15 years Yes
Primary Maximum tolerated dose of Ad5CMV-p53 gene Evaluated by the frequency and relationship of dose-limiting toxicities, if any, experienced by patients during dose escalation. 6 months Yes
Primary Pharmacodynamics evaluated by examining the injected precancerous lesion for induction of apoptosis and expression of the p53 protein Presented using descriptive statistics, frequency tabulations, and graphical displays over time by treatment cohort. 168 days No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03656133 - Use of a Proliferation Saturation Index to Determine Personalized Radiotherapy for HPV + Oropharyngeal Cancers N/A
Terminated NCT02225496 - Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma Phase 2
Withdrawn NCT01767961 - Modified Barium Swallow in Measuring Swallowing Function After Surgery in Patients With Oropharyngeal Cancer N/A
Completed NCT01695122 - Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma Phase 2
Completed NCT01435252 - A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab Phase 2
Recruiting NCT04708470 - A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers Phase 1/Phase 2
Withdrawn NCT00951470 - Complete Decongestive Therapy (CDT) for Treatment of Head and Neck Lymphedema N/A
Completed NCT01358097 - Role of Immune Activation in Response of Head and Neck Squamous Cell Carcinoma to Therapy N/A
Completed NCT00964977 - Effectiveness of Adjuvant Radiotherapy in Small Oropharyngeal Squamous Cell Cancer and Single Lymph Node Metastasis. Phase 3
Completed NCT01342978 - Human Papillomavirus (HPV) Oral Transmission Study in Partners Over Time N/A
Recruiting NCT05363709 - BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients Phase 2
Completed NCT02280811 - T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers Phase 2
Active, not recruiting NCT03777384 - EValuating the Safety Of De-escaLated Head and Neck Irradiation in HPV positivE Oropharynx Cancer in Non-smokers/Minimal Smokers
Active, not recruiting NCT03729518 - TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck N/A
Recruiting NCT06121102 - Standard Pulsed Radiofrequency Versus Supervoltage Pulsed Radiofrequency Glossopharyngeal Nerve in Oropharyngeal Cancer Pain N/A
Recruiting NCT02984410 - Study Assessing The "Best of" Radiotherapy vs the "Best of" Surgery in Patients With Oropharyngeal Carcinoma N/A
Recruiting NCT02960724 - uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer Phase 2
Completed NCT02934724 - Impact of HPV Vaccine On The Prevalence Of HPV In Norway
Withdrawn NCT00928161 - Reflux Disease in Head and Neck Cancer Patients Undergoing Radiation Therapy N/A
Recruiting NCT02012699 - Integrated Cancer Repository for Cancer Research